论文部分内容阅读
目的观察重组人白细胞介素-1(1rhIL-11)对慢性难治性特发性血小板减少性紫癜(ITP)的疗效和安全性。方法慢性难治性ITP患者皮下注射rhIL-1150ug/kg,1次/d,疗程14d。结果32例患者用药前血小板计数平均值为(15.3±7.8)×109/L,给药后7、10、14d分别升至(38.6±17.0)×109/L(,52.6±26.5)×109/L(,66.5±34.4)×109/L,与用药前相比有显著升高(P<0.01)。停药后血小板逐渐回落,2个月后降至(52.0±30.2)×109/L,但仍然显著高于治疗前(P<0.01)。治疗的总有效率75%,12例出现轻微不良反应。结论rhIL-11治疗某些慢性难治性ITP有较好疗效,不良反应轻微。
Objective To observe the efficacy and safety of recombinant human interleukin-1 (IL-11) on chronic intractable idiopathic thrombocytopenic purpura (ITP). Methods Chronic intractable ITP patients were injected rhIL-1150ug / kg subcutaneously once daily for 14 days. Results The average value of platelet count before treatment in 32 patients was (15.3 ± 7.8) × 109 / L, and the values were (38.6 ± 17.0) × 109 / L (52.6 ± 26.5) × 109 / L (66.5 ± 34.4) × 109 / L, which was significantly higher than that before treatment (P <0.01). The platelets decreased gradually after stopping treatment, and dropped to (52.0 ± 30.2) × 109 / L after 2 months, but still significantly higher than those before treatment (P <0.01). The total effective rate of treatment was 75%, 12 patients showed mild adverse reactions. Conclusion rhIL-11 is effective in treating some chronic refractory ITP patients with mild adverse reactions.